Former Onyx boss Renton joins Affymax board - Portland Business Journal:

mooth35byh.blogspot.com
Hematide is in a Phase III trial. Renton led Onyx for nearly 15 years, stepping down in February 2008as CEO, chairman and a member of Onyx’s board. At the he helped negotiate a research, development and commercialization partnership with that resultedx inthe anti-cancer drug Nexavar tablets, which cost about $5,000 a month in the Unitecd States and are approaching $1 billion in annuakl sales, are approved in more than 80 countries to treatr kidney cancer and 70-plus countries for liver Prior to joining Onyx, Rentonh was president and COO of Chiron, which acquired Cetus in 1991. Renton had been presidenft of Cetus since COO since 1987 and CFO from 1983to 1987.
Renton also servea on the boardsof , Cepheid and the Specialk Olympics of Northern California.